Sugi Predict

Sugi Predict / Compounds / SCHEMBL16636969

SCHEMBL16636969

SCHEMBL16636969

COC(=O)C1CN(c2ncnc3cc(Cl)c(Br)cc23)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.47
▸ NR1H3 Q13133 1/20 0.47
▸ PDGFRB P09619 12/20 0.41
▸ MAP4K4 O95819 1/20 0.39
▸ PDGFRA P16234 5/20 0.38
▸ KIT P10721 2/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ MAPK1 P28482 1/20 0.37
▸ ENPP1 P22413 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ BACE1 P56817 1/20 0.37
▸ MALT1 Q9UDY8 1/20 0.37
▸ PDE10A Q9Y233 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16637144 0.91 MAP4K4 (0.40) NR1H2NR1H3PDGFRBMAP4K4PDGFRA
SCHEMBL16636620 0.90 MAP4K4 (0.41) NR1H2NR1H3PDGFRBMAP4K4PDGFRA
SCHEMBL16636985 0.88 NR1H2 (0.47) NR1H2NR1H3MAP4K4BACE1
SCHEMBL16636963 0.86 NR1H2 (0.46) NR1H2NR1H3PDGFRBMAP4K4PDGFRA
SCHEMBL30569574 0.86 NR1H2 (0.46) NR1H2NR1H3PDGFRBMAP4K4PDGFRA
SCHEMBL16636961 0.86 NR1H2 (0.46) NR1H2NR1H3PDGFRBMAP4K4PDGFRA
SCHEMBL16637110 0.81 KIT (0.52) PDGFRBMAP4K4PDGFRAKITFLT3
SCHEMBL30902163 0.81 KIT (0.52) PDGFRBMAP4K4PDGFRAKITFLT3
SCHEMBL16637087 0.79 NR1H2 (0.36) NR1H2NR1H3MAP4K4
SCHEMBL16637206 0.78 MAP4K4 (0.40) NR1H2NR1H3MAP4K4KITMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20220242875-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2022-08-04 — — US disclosed
US-20210188869-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2021-06-24 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188869-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885PDGFRB 1746/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS NR1H2 3336/4885NR1H3 3617/4885PDGFRB 575/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS NR1H2 3409/4885NR1H3 3275/4885PDGFRB 1938/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 3409/4885NR1H3 3275/4885PDGFRB 1938/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885PDGFRB 1746/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885PDGFRB 1746/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885PDGFRB 1746/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885PDGFRB 1746/4885
US-20220242875-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS NR1H2 2945/4885NR1H3 3105/4885PDGFRB 1746/4885
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS NR1H2 3475/4885NR1H3 3244/4885PDGFRB 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.